Industry Overview

European artificial tear market is projected to experience steady growth from $1,150.0 million in 2025 to $1,754.8 million by 2035, reflecting a compound annual growth rate (CAGR) of 4.4% forecast period (2026-2035). The market is expanding due to factors like the increasing prevalence of dry eye syndrome, a growing elderly population, and rising screen time from digital devices. Key growth drivers also include advancements in product formulations, such as preservative-free and lipid-based drops, and greater awareness of eye health.

Market Dynamics

Rising Dry Eye Disease (DED) Prevalence and Ageing Population

One of the most significant drivers of the European artificial tear market is the rising prevalence of dry eye disease across all major European countries. Ageing demographics across Germany, France, Italy, and the UK have accelerated the demand for long-term ocular surface management solutions, as older adults are more susceptible to tear film instability and meibomian gland dysfunction. Increased diagnosis by ophthalmologists and optometrists, coupled with better disease awareness among consumers, has strengthened the continuous uptake of artificial tears, particularly preservative-free formulations suitable for chronic daily use. This demographic trend ensures a stable long-term customer base and contributes consistently to market expansion.

Increased Digital Device Usage and Environmental Stressors

The growing dependence on digital screens, computers, smartphones, and tablets has significantly contributed to evaporative dry eye symptoms among younger and working-age populations across Europe. Longer screen exposure reduces blink rates, causing ocular discomfort and prompting consumers to seek over-the-counter lubricating drops. Additionally, modern environmental conditions such as indoor air-conditioning, pollution in urban centers, and extended contact lens use have collectively driven higher rates of occasional and mild-to-moderate dry eye symptoms. This behavioral and environmental shift has expanded the market beyond elderly users to include a broader and younger consumer segment, thereby increasing overall product demand.

Shifting Consumer Preference Toward Preservative-Free and Premium Formulations

Another key driver is the rapid transition toward preservative-free, high-viscosity, and specialized artificial tear products across European markets. Consumers and healthcare professionals increasingly prefer preservative-free single-dose vials and multi-dose sterile systems due to reduced risk of ocular irritation, especially for chronic users. Product innovations such as advanced hyaluronic acid concentrations, lipid-based emulsions, and formulations tailored for specific dry eye subtypes have supported market premiumization. Stronger retail pharmacy networks, expanded e-commerce penetration, and improved reimbursement pathways in selected European countries have made premium and specialty products more accessible. These combined factors enhance product adoption and fuel sustained market growth across the region.

Market Segmentation

• Based on type, the market is segmented into glycerin?derived tears, cellulose?derived tears, oil?based / emulsion?based tears, polyethylene glycol (PEG)-based tears, propylene glycol-based tears, and hyaluronic acid.
• Based on the delivery method, the market is segmented into eye drops and ointments.
• Based on the application, the market is segmented into dry eye syndrome, digital eye strain, and contact lens discomfort/moisture retention.
• Based on the end user, the market is segmented into retail pharmacies (OTC), online pharmacies, hospitals & ophthalmic clinics, and others.

Preservative-Free Drops Segment to Lead the Market with the Largest Share

Among all the segments in the European artificial tear market, the preservative-free drops segment (under by type) emerges as the largest and leading segment, primarily due to Europe’s strong clinical preference for safer, long-term dry eye management solutions. The region has witnessed a rising incidence of chronic Dry Eye Syndrome driven by aging populations, high screen-time exposure, and increasing post-surgical ocular treatment conditions that often require frequent and prolonged artificial tear use. Preservative-free formulations are widely recommended by ophthalmologists across Germany, France, the UK, Italy, and Spain because they eliminate the risk of preservative-induced ocular surface irritation, making them suitable for sensitive eyes and long-duration therapy.

Additionally, the rapid expansion of single-dose vials, multi-dose preservative-free bottle technology, and growing consumer awareness about ocular safety have strengthened their adoption across both retail and online pharmacies. As a result, preservative-free drops command the largest share and continue to drive market revenue more than other segments, such as glycerin-based tears, gels, ointments, or delivery modes like eye drops and ointments, firmly positioning them as the dominant segment in the European Artificial Tear Market.

Eye Drops: Key Segment Driving Market Growth

Among all the segments in the European artificial tear market, eye drops under the delivery mode category stand out as the single most influential segment driving market growth. Eye drops dominate due to their convenience, rapid onset of action, wide availability, and strong patient preference for self-administration. As dry eye syndrome, digital eye strain, and allergy-related irritation become increasingly common across Europe, eye drops remain the most frequently recommended first-line therapy by ophthalmologists. Their non-invasive nature and ability to provide instant lubrication make them suitable for daily use, thereby increasing repeat purchase cycles and boosting overall market value.

Moreover, the growing elderly population, which is more prone to chronic dry eye, continues to drive steady demand for easy-to-use formats like drops. The expansion of preservative-free formulations packaged in single-dose vials and multi-dose systems has further accelerated adoption, appealing to consumers seeking safer long-term solutions. Eye drops also dominate sales across retail and online pharmacy channels, supported by aggressive marketing from leading brands and frequent product innovations, especially in advanced polymer and hyaluronic acid-based formulations. Overall, eye drops remain the backbone of the artificial tear market, accounting for the largest share and representing the strongest driver of sustained market expansion through 2035.

Regional Outlook

European artificial tear market is further divided by countries, including the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe.

Germany Dominates the Market with a Major Share

Germany dominates the European artificial tear market with a major share, driven by its strong healthcare infrastructure, high awareness of ocular health, and a large patient population affected by dry eye syndrome and digital eye strain. As one of the most advanced pharmaceutical and medical device markets in Europe, Germany benefits from robust distribution networks, a high reimbursement capacity, and widespread accessibility of OTC and prescription-based artificial tears. The country’s aging population, one of the fastest-growing in the region, significantly contributes to the demand for long-term lubrication products, including hyaluronic acid-based and preservative-free formulations.

Moreover, Germany’s high digital device usage among working professionals and students has intensified cases of screen-related eye discomfort, further boosting artificial tear consumption. Strong clinical adoption in ophthalmic clinics, advanced R&D activities, and the presence of leading global and domestic brands enhance the country’s dominance. Germany also serves as a key launchpad for innovative artificial tear technologies due to stringent quality standards and high consumer willingness to adopt premium products. Additionally, well-established e-commerce and retail pharmacy channels support continuous product availability and repeat purchases. Overall, Germany’s demographic trends, economic strength, and healthcare advancements firmly position it as the leading market in Europe.

Market Players Outlook

The major companies operating in the European artificial tear market include Alcon Inc., Allergan (AbbVie Inc.), Bausch & Lomb, Johnson & Johnson, Santen Pharmaceutical Co., Ltd., among others. Market players are leveraging partnerships, collaborations, mergers, and acquisition strategies for business expansion and innovative product development to maintain their market positioning.

Recent Developments

• In March 2025, Labtician Ophthalmics launched Lab TRIACTIV, a preservative-free artificial tear designed for dry eye relief with a longer-lasting effect and compatibility with contact lenses, requiring fewer applications. President Polydor Strouthos commented on the launch in a company press release.
• In October 2024, Novaliq and Laboratoires Théa received European Commission approval for ciclosporin 0.1% eye drops solution (Vevizye) to treat dry eye disease (DED). Laboratoires Théa will commercialize the product in Europe and select Middle Eastern and North African countries. The product was previously approved by the FDA in May 2023. Vevizye is intended for moderate to severe DED in adults unresponsive to tear substitutes. Its efficacy was demonstrated in the ESSENCE-1 and ESSENCE-2 clinical trials, which involved randomized, multicentre studies measuring total corneal fluorescein staining score. ESSENCE-2 included 834 patients and compared the results of ciclosporin versus a vehicle after treatment.
• In January 2025, Alcon launched Systane Complete Preservative-Free Lubricant Eye Drops in Europe, enhancing its portfolio of dry eye products. This new product is available in a multi-dose bottle and marks Alcon's commitment to the growing artificial tears market, valued at around $1 billion in annual sales. The preservative-free segment is the fastest-growing, making up over 40% of artificial tears sales.

The Report Covers

• Market value data analysis of 2025 and forecast to 2035.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the European artificial tear market. Based on the availability of data, information related to new products and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.